Full-body scans: which startup is ahead?

Which full-body scan startups actually belong in this comparison?

The serious full-body scan startup field currently includes Neko Health, Prenuvo, Function Health through Ezra, Q Bio, Biograph and OneMRI.

These companies compete for the same customer: someone willing to pay privately for a broad health check before symptoms appear. Their products differ. Prenuvo, Function/Ezra, Q Bio, Biograph and OneMRI put MRI at the center of the examination. Neko uses its own cameras, cardiovascular sensors, blood tests and other measurements without any MRI. Neko still belongs here because customers often choose between its scan and a more expensive whole-body MRI.

Ezra has been part of Function Health since Function acquired it in May 2025, so we treat Function/Ezra as one competitor. Function brings a large preventive-health membership, while Ezra supplies the imaging product and the partner network. (PR Newswire)

We exclude traditional radiology groups, hospital screening departments and older executive-health providers. We also exclude Fountain Life, Human Longevity and Echelon Health, because full-body scanning is one part of a broader concierge service rather than the core product. Biograph stays in scope because its business is young, independently funded and built almost entirely around advanced preventive testing.

Funding figures for private startups are uneven. Company announcements give firm numbers for Neko and Function, while Prenuvo’s total comes from management statements. Neko confirmed in July 2026 that its Series C took total funding above $1 billion but did not disclose a valuation; the Financial Times reported it at nearly $7 billion. Function’s July 2026 financing is revenue-based growth capital, not a new equity round, so it does not change the $2.5 billion valuation set in November 2025. (Neko Health)

Startup	What the company currently sells	Disclosed cumulative funding
Neko Health	One-hour skin, cardiovascular, blood and metabolic assessment with a same-visit clinician consultation, now in Sweden, the UK and New York	About $1.025B, including a $65M Series A, $260M Series B and $700M Series C in July 2026 (TechCrunch)
Function Health / Ezra	MRI and CT scans connected to Function’s recurring laboratory-testing membership	About $350M in equity raised by Function, plus $450M in revenue-based growth financing in July 2026; Ezra had raised about $43M before the acquisition (HLTH)
Prenuvo	Head-to-ankle whole-body MRI, blood panels and clinical review	About $250M according to Prenuvo management; no new round disclosed in 2026 (New York Post)
Q Bio	Whole-body MRI, biomarkers, genetics, wearable data and physician review	About $80M (Tracxn)
Biograph	Premium preventive-health membership combining MRI with 20 to 30-plus assessments	About $53.9M according to PitchBook data reported by SFGATE (SFGATE)
OneMRI	Partner-delivered whole-body MRI across Australia	A$2.5M seed round (OneMRI)

Is anyone clearly ahead in full-body scans today?

The full-body scan market has a clear top two: Prenuvo leads dedicated whole-body MRI, while Neko Health leads the broader preventive body-scan race.

Prenuvo has completed more MRI scans, runs a specialized radiology operation and offers the deepest standardized view of internal anatomy. It reported more than 200,000 completed scans in September 2026, and its affiliated radiology group includes more than 100 board-certified radiologists. Its North American network now lists 26 sites, 25 of them in the United States. No other startup has shown comparable MRI volume. (Prenuvo)

Neko is moving faster as a consumer-health company. Its examination costs far less, most customers book another visit before leaving, and it now has roughly four times Prenuvo’s disclosed capital. Neko also controls the cameras, sensors, software and clinic, so it can improve the examination on its own schedule. In September 2026 it took that model to the United States for the first time. (Neko Health)

Function/Ezra sits in third place. The combined company sells lower-priced MRI through a large partner network and can market those scans to hundreds of thousands of Function members. Function has never disclosed how many members actually bought an MRI, so its reach still lacks a matching scan-volume figure. (Ezra)

The structure is stable. Prenuvo and Neko have separated from the field through real examination volume. Function has the strongest route into the leading group, while Q Bio, Biograph and OneMRI lead narrower niches.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Which full-body scan startup has served the most people?

Prenuvo has the largest customer base in full-body MRI, with more than 200,000 completed scans.

Prenuvo reported more than 150,000 scans at the start of 2026, more than 170,000 in March 2026 and more than 200,000 on 29 September 2026, when it launched a research network built on its imaging biobank. That implies roughly 50,000 scans in about nine months, although the exact counting dates may differ from the publication dates. The figure is the company’s own; trade press repeated it, but we found no independent count. (Prenuvo)

Neko says more than 100,000 people have had its scan in Sweden and the United Kingdom. It repeated that figure in its July 2026 funding release and again at its New York opening in September 2026, so the published total has not moved in three months. Neko reached it from eight European clinics before its American launch. (Neko Health)

Function says hundreds of thousands of people use its laboratory-testing membership. That number is not imaging volume. Members must buy a scan separately, and neither Function nor Ezra reports how many do. An August 2026 industry analysis estimated 300,000 to 450,000 active Function subscribers, which is an outside estimate, not a company figure.

Q Bio, Biograph and OneMRI have live products, but none has released a comparable customer count. Biograph says it has served thousands of members since 2020 without giving an exact total. OneMRI now lists 12 Australian cities and more than 50 partner clinics, which tells us about availability rather than completed examinations. (SFGATE)

Startup	Latest useful volume figure	What we can safely conclude
Prenuvo	More than 200,000 scans (company figure, September 2026)	Largest whole-body MRI customer base
Neko Health	More than 100,000 people scanned (company figure, repeated September 2026)	Second-largest disclosed preventive-scan base and the largest non-MRI operator
Function / Ezra	MRI volume undisclosed	Large membership and broad availability, with no public scan conversion rate
Biograph	Thousands of members	Real premium demand, still far below the two leaders
Q Bio	Undisclosed	Commercially available from one clinic and enterprise partners, with little evidence of scale
OneMRI	Undisclosed	Wide availability across 12 Australian cities, with completed volume unknown

Can Neko Health repeat its European growth in the United States?

Not yet proven. Neko grew fastest in Europe, but its American growth is only beginning and has no public numbers yet.

Neko had completed 10,000 examinations by early 2025 and passed 100,000 around 18 months later. We calculate that it added roughly 90,000 examinations in that period, close to 5,000 per month. The first 10,000 had taken nearly two years, around 435 per month. On those rough averages, Neko raised its monthly throughput more than elevenfold. (Neko Health)

That growth came from opening clinics, not just from sign-ups. Neko went from Stockholm and one London site to four London clinics, Manchester and Birmingham. Its newer devices automate more of the examination and reduce the load on clinical staff. (Neko Health)

The next test started on 24 September 2026, when Neko opened a seven-room clinic at 300 Lafayette Street in New York. More than 25,000 New Yorkers had joined the waiting list by then, and the New York Post put the list above 50,000 in October, based on company figures. The scan costs $499 and accepts HSA and FSA payments. Neko says more New York sites, Miami, Washington, D.C. and San Francisco will follow over the next year; those are plans, not open clinics. The launch also came later than the spring 2026 opening Neko had signalled at the start of the year.

Prenuvo is now adding scans at a similar pace, moving from more than 150,000 at the start of 2026 to more than 200,000 by September, while Neko repeated the same 100,000 figure in July and September. Function/Ezra could grow faster still because it rents capacity in existing MRI centers. Until Function publishes scan purchases and Neko publishes American volumes, Neko’s European record remains the clearest evidence of how fast a new clinic network can scale. Our view: one clinic and a waiting list do not prove that the model travels, but Neko has the money to find out quickly.

Which full-body scan company has the strongest proof that customers come back?

Neko Health has the best disclosed evidence of repeat demand in preventive body scanning.

Neko says 75% of members book and prepay their next annual scan before leaving the clinic, and that 80% of those who come back for a second visit then book a third. The company had reported an 80% first rebooking rate when it was much smaller. A five-point decline while volume rose tenfold suggests repeat demand has held up well during expansion. (Neko Health)

Neko has also drawn more than 350,000 people to its waiting and registration pool, around 3.5 interested people for every person scanned. A waiting list can include inactive or duplicate interest, so we give more weight to prepaid bookings. Still, the combination shows that Neko faces a capacity problem, not a demand problem.

Prenuvo moved from one-off scans to annual memberships in March 2026, bundling MRI, laboratory tests and clinical reviews. Memberships include up to two screenings a year. That should lift repeat usage, but Prenuvo has not released a renewal or rebooking rate. Its more than 200,000 completed scans prove large demand at a much higher price, even without a retention number. (Prenuvo)

Function has hundreds of thousands of paying laboratory members, an unusually large audience for MRI upselling, and it now offers members up to $200 off imaging. It still needs to show how many members add a scan and how many repeat it. Until it does, Function’s membership cannot outweigh Neko’s prepaid renewal data.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Is Neko’s $499 US scan cheaper than a full-body MRI?

Yes. Neko Health is the cheapest broad preventive scan on both sides of the Atlantic, while Function/Ezra still offers the lowest widely available MRI price among the larger competitors.

Neko charges £299 in the United Kingdom and $499 in New York for a one-hour visit covering skin, heart, circulation, blood and metabolic health, including more than 50 blood biomarkers. The price sits far below MRI services because Neko does not need an MRI machine or a radiologist for every customer. (Neko Health)

Function members pay $899 for the basic annual MRI, against a public price of $999. Membership costs $365 for the first year. The scan takes as little as 22 minutes and covers the head, neck, abdomen and pelvis. An option with the spine costs $1,499 for members and lasts about 47 minutes. (Function Health)

Prenuvo charges $2,499 for its full whole-body MRI, either as a membership or as a standalone scan. Its $1,199 Core tier uses a shorter head-to-mid-thigh protocol and leaves out the arms, spine and aneurysm assessment. Prenuvo costs more because the full examination covers more anatomy and runs on a more controlled clinical workflow. (Prenuvo)

The answer depends on what the customer wants. Neko wins for an annual broad health check. Function wins for entry-level MRI. Prenuvo offers a more complete MRI for customers willing to pay close to three times Function’s entry price. Neko’s US price is close to double its UK price, but it is still roughly half the cheapest member MRI.

Company and product	Current listed price	What the customer receives
Neko Health Scan	£299 (UK); $499 (New York)	Skin, cardiovascular, blood and metabolic assessment; no MRI
Function/Ezra Annual MRI	$899 for Function members	Head, neck, abdomen and pelvis; up to 13 organs
Prenuvo Core	$1,199	Head-to-mid-thigh MRI and laboratory panel; spine and arms excluded
Prenuvo Comprehensive	$2,499	Whole-body MRI, laboratory testing and follow-up review
OneMRI	A$2,990	Whole-body MRI, radiologist report and doctor consultation (OneMRI)
Biograph Core	$7,500	Whole-body MRI plus more than 20 other assessments (Biograph)

Which full-body scan company gives the most complete examination?

Prenuvo offers the strongest standardized whole-body MRI, while Biograph provides the broadest overall preventive-health workup.

Prenuvo’s full protocol covers the head, brain, major organs, spine and much of the musculoskeletal system down to the ankles. The scan uses several MRI sequences over about 50 to 60 minutes. The membership adds laboratory tests and a provider review, and add-ons now cover brain health, body composition and heart health. (Prenuvo)

Biograph goes wider across types of testing. Its $7,500 Core membership combines whole-body MRI with a blood panel, DEXA body-composition imaging, VO₂ max testing and a physician-led review. Its Black tier now costs $17,500 for the first year and adds coronary CT angiography, low-dose lung CT, a multi-cancer blood test, mid-year labs and continuous glucose monitoring. (Biograph)

Q Bio has the most coherent multimodal design among the smaller companies. Its Q Exam brings together whole-body MRI, more than 120 blood biomarkers, 163 risk-related genes, wearable data, prior medical records and a 45-minute physician review, stored in a dashboard built for year-over-year comparison. Q Bio still lists one clinic, in Redwood City, plus unnamed enterprise partners, which keeps a strong product from becoming market leadership. (Q Bio)

Neko covers fewer internal structures than MRI. Its strengths are speed, price and repeated measurement of common cardiovascular, metabolic and skin risks, including a 360-degree skin exam. A healthy 35-year-old looking for an annual baseline may get more use from Neko than from an expensive MRI, even though the examination sees less anatomy.

Biograph delivers the largest testing bundle, Prenuvo the deepest standardized MRI, and Neko the most accessible recurring checkup. Those are three different kinds of completeness.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Which full-body scan product is actually ready for routine paid use?

Prenuvo and Neko Health are the only full-body scan startups operating at proven six-figure examination scale.

Both run standardized consumer services, not pilots, and both now operate in the United States. Function/Ezra is also commercially available across a large partner network, but it has not disclosed enough scan volume to show comparable adoption. Q Bio, Biograph and OneMRI remain smaller or more specialized.

Which full-body scan company has the best clinical evidence?

Prenuvo has the deepest company-specific clinical evidence, yet the research still falls short of proving that routine whole-body MRI helps average-risk people live longer.

Prenuvo studied 1,011 people who had a screening whole-body MRI and about 12 months of follow-up. Biopsies confirmed cancer in 2.2% of them. The company estimated that 64% of detected cancers were localized and that 68% appeared in organs without established screening programs. Those results are promising, especially for kidney, bladder and lymphoma detection, but the retrospective study came from Prenuvo’s own clinical network. (Prenuvo)

Prenuvo has started using its much larger dataset for wider research. One analysis covered 118,019 scans across the United States and Canada, and another reviewed brain findings in 78,800 people. These datasets show scale and can improve reporting standards, but retrospective reviews of findings cannot show whether population screening lowers deaths or healthcare spending. (Prenuvo)

Independent research remains cautious. A meta-analysis of ten studies covering more than 9,000 people without symptoms found a pooled cancer-detection rate of 1.57%. The authors also found frequent incidental findings, inconsistent protocols and little evidence on cost-effectiveness or long-term outcomes. (European Radiology)

The American College of Radiology still says there is not enough evidence to recommend total-body MRI for people without symptoms, relevant risk factors or a suggestive family history. A more recent Radiological Society of North America review reached the same basic conclusion while noting that consumer demand keeps rising. (American College of Radiology)

Neko’s evidence answers a different question. The company followed 1,469 people who returned for a second examination and found improvements in blood pressure, cholesterol and blood sugar. With no control group, we cannot tell how much came from Neko, medication changes, healthier habits or the type of person who chooses to return. (Neko Health)

Prenuvo has the largest clinical dataset, Neko has encouraging longitudinal observations, and the other startups have published very little outcome research. None has made a general medical case for annual scanning of healthy people.

Which full-body scan company handles false positives best?

Prenuvo has the strongest system for sorting MRI findings, while Neko gives customers faster face-to-face explanation.

Prenuvo uses specialist radiologists and standardized risk categories. Neko reviews results with a clinician in the same visit and, in New York, refers members who need more care to hospital partners including Columbia University Irving Medical Center and Mount Sinai. No independent comparison shows which service causes fewer unnecessary follow-up tests, so neither has proved a clear clinical advantage here.

Who can bring full-body scans to the most cities?

Function/Ezra offers the widest MRI access through its partner imaging network.

Function now advertises 200 imaging locations, while Ezra’s own page still says more than 170, so the exact count depends on which company page you read. Prenuvo has a smaller but more controlled network of 26 North American sites. OneMRI uses a partner model across Australia, while Neko builds its own clinics and expands more slowly. Function leads on availability, but Prenuvo offers more consistency.

Which partnerships show real commercial strength in full-body scans?

Function has the strongest mass-distribution relationships, while Prenuvo has built the more medically credible partnerships.

Function links laboratory access through more than 2,000 Quest Diagnostics locations with its imaging partner network. In July 2026 General Catalyst’s Customer Value Fund agreed to finance its customer acquisition with $450 million, repaid from a capped share of the revenue those customers bring in. That gives Function the broadest funnel and money to fill it, even though it still does not disclose how many members buy scans. (Function Health)

Prenuvo works with primary-care providers such as Baker Health and Parsley Health, and John Hancock offers some customers discounted access. Those relationships help with referrals and follow-up but have not produced broad insurance coverage. Neko’s New York referral links to Columbia and Mount Sinai are new and show it can plug into American hospital systems. (Prenuvo)

What can the leading full-body scan startups do that hospitals cannot easily copy?

Neko’s integrated hardware and clinic system is the hardest to copy, while Prenuvo owns the strongest specialized whole-body MRI dataset.

Hospitals already offer MRI, but they rarely combine standardized protocols, consumer-friendly reports, year-over-year comparison and a smooth annual membership. Neko controls the sensors, software, app and clinic. Prenuvo has built expertise from more than 200,000 similar scans and, in September 2026, opened that biobank to a research network with collaborators from more than 50 institutions. Function controls the recurring health record while using outside laboratories and imaging centers.

The scan itself is widely available. Making results consistent, understandable and useful enough that customers return is the real advantage.

If you want more recent data on this point, see the latest figures in our Longevity report ↓.

Which full-body scan startup is turning funding into real output most efficiently?

Prenuvo has turned funding into completed scans more efficiently than Neko.

Prenuvo has raised about $250 million and completed more than 200,000 scans, roughly $1,250 of funding per scan. Before its July 2026 Series C, Neko had raised about $325 million and scanned more than 100,000 people, about $3,250 per scan. Counting the Series C, Neko’s ratio rises above $10,000 per scan.

These ratios are rough and are not unit economics. Neko’s $700 million is meant to fund future clinics, starting with New York, while Prenuvo has already deployed most of its capital. Function’s $450 million is a different instrument again, tied to the revenue of new customers. Still, Prenuvo has produced the most visible output from the smallest funding base.

Can hospitals and radiology chains catch up with the full-body scan startups?

Large radiology chains can catch up quickly on MRI availability, but matching the full consumer experience will take longer.

Existing providers already own scanners and employ radiologists. Their weak spots are usually online booking, standardized preventive protocols, readable reports, follow-up coordination and year-over-year comparison.

Prenuvo, Neko and Function have spent years building those layers. A major healthcare group that combined its imaging capacity with strong consumer software and trusted doctors would still be a serious threat.

Can Function Health’s $450M push Ezra into the full-body scan top two?

Function/Ezra could break into the top two, but only by publishing strong MRI conversion and repeat-purchase numbers, not by raising money.

The July 2026 financing gives Function the means to market scans hard to its members. Neko must now prove that its European clinic model works in the United States, where it has one open clinic. Prenuvo could regain first place by lowering prices or producing stronger evidence that screening improves long-term outcomes. Q Bio remains the technical wildcard if its faster quantitative scanner reaches wider commercial use.

Which full-body scan startups are actually ahead?

Neko Health is ahead overall, Prenuvo remains the clear whole-body MRI leader, and Function/Ezra is the only challenger close enough to change the top two quickly.

We place Neko first because it combines fast examination growth, strong prepaid renewals, low prices, its own hardware and more than $1 billion raised, and in September 2026 it began its American rollout. Its limits are just as clear: its scan cannot see internal anatomy with the depth of an MRI, and its US business has no public volume yet.

Prenuvo takes second place by a narrow margin. It has completed more scans, built the strongest radiology operation and produced the category’s deepest research base. It loses the overall lead because its core product still costs $2,499, hard to justify as a routine annual purchase for most people.

Function/Ezra ranks third. Its 22-minute MRI, lower price, nationwide partner network, large membership and $450 million of growth financing give it real potential. We would move Function higher once it shows how many members buy scans and come back for another one.

The gap below the top three is wider. Q Bio has an excellent technical concept with limited commercial proof. Biograph leads the luxury end and has raised its top tier to $17,500, with little reason to chase volume. OneMRI is a capable regional operator that remains early.

Rank	Startup	Why it ranks here now
1	Neko Health	Best overall combination of growth, repeat demand, affordability, proprietary technology and capital; first US clinic opened in New York in September 2026. The product remains less anatomically detailed than MRI
2	Prenuvo	Largest dedicated whole-body MRI operator, strongest clinical infrastructure and deepest evidence base. High pricing keeps it just behind Neko overall
3	Function Health / Ezra	Widest MRI access, fastest entry-level scan, strongest built-in distribution and $450M of growth financing. Public imaging-volume and retention data remain missing
4	Q Bio	Strongest quantitative and multimodal product vision among the smaller companies. Deployment and customer scale remain too limited
5	Biograph	Most complete premium preventive-health service, with strong physician support. Its $7,500 to $17,500 model targets a small wealthy market
6	OneMRI	Broad Australian partner footprint across 12 cities and solid execution for a seed-funded startup. Completed scan volume, clinical evidence and international reach remain limited

If you want more recent data on this point, see the latest figures in our Longevity report ↓.